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powered  for  the questions  raised  in  this paper,  the present data  suggest  some 
refinement in the management protocol of early IUGR fetuses delivered before 32 
weeks of gestation: 
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54 34 11 99   (32%)





          Spontaneous decel        24                 22       33  
          ReDV >30 weeks          2                   4          1  
Other fetal indications         9        15                 22   46 (15%)
Maternal  16 13 18 47 (15%)
Total  105 99 106  310






















Table 2: Number of infants with normal neurological follow-up and total number with known 
outcome, specified for the indication of delivery and randomization allocation. Selected were 
only infants delivered before 32 weeks, fetal death due to inevitable poor prognosis and neonatal 
death due to a lethal anomaly were excluded. In ’total including fetal death’ the 7 antepartum 
deaths were included and in ‘total, survivors only’ outcome in the 285 survivors is  shown 
 
Indication for delivery  c‐ CTG      STV  DV p95  DV no A  All 
According to randomization 















































































Table 3: Sub-division of safety net criteria for randomization allocation for infants with normal  
or abnormal neurological follow-up at 2 year’s of age and total number. ReDV= reversed end-
diastolic velocities umbilical artery 
Safety-net indications for delivery c-CTG  STV DV p95 DV no A Total 
Low STV* only          -            2 12 14 
                Normal outcome - 1 9 (71%) 
                Abnormal outcome - 1 3  
Decelerations only 24 22 33        79 
                Normal outcome 13 20 27 (76%) 
                Abnormal outcome 11 2 6  
Low STV* with decelerations - 9  9  18 
                Normal outcome - 9 9 (100%) 
                Abnormal outcome - 0 0  




          7    
                 Normal outcome 2 4 1 (100%) 
                 Abnormal outcome 0 0 0  
Total 26 37 55 118  
                 Normal outcome 15 (58%) 34 (92%) 46(84%) (81%) 
                 Abnormal outcome 11 (42%) 3 (8) 9 (16%)  




















N  c‐CTG  DV p95  DVnoA  All 
N    105  99  106  310 
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